&lt;Diapulse Corp of America>said it has received permission to resume marketing itsDiapulse pulsed high peak power electromagnetic energy medicaldevice for treatment of postoperative edema and pain insuperficial soft tissues.    The company said it had been enjoined from marketing theproduct in the U.S. since 1972 due to a labeling impasse withthe U.S. Food and Drug Administration.    It said the U.S. District Court for the Eastern District ofNew York modified an injunction against sale of the productfollowing a motion filed jointly by the company and the FDA. Reuter&#3;